博瑞医药(688166.SH)上半年净利润1717.32万元，同比下滑83.85%

Core Viewpoint - 博瑞医药 reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its business performance [1] Financial Performance - The company achieved an operating revenue of 537 million yuan, representing a year-on-year decrease of 18.28% [1] - The net profit attributable to shareholders was 17.17 million yuan, down 83.85% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 14.37 million yuan, reflecting a year-on-year decline of 86.35% [1]